Hey Zwartkops, hate to be the glass half empty guy but I read online that the median phase 3 trial costs $19 million.
LCTs entire market cap is $14 million!
So they need to find the funds to pay for the trial that is more than their MC. If they manage to do this then this would be great and you might be right.
I still have a feeling you did well to buy shares at these low prices, and I’ll congratulate you when the SP is in the teens again.
Ann: NTCELL Parkinsons trial 2 year data analysis shows success, page-17
-
- There are more pages in this discussion • 100 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $1.4K | 199.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 6404404 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1428102 | 2 |
View Market Depth
| Last trade - 11.17am 11/10/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |